Roumen D. Balabanov

Neurology

259 E Erie St Ste 1900
Lavin Family Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Preserved neurovascular coupling in early multiple sclerosis is associated with reduced white matter lesion burden.

Preserved neurovascular coupling in early multiple sclerosis is associated with reduced white matter lesion burden.

Journal: Therapeutic advances in neurological disorders

Published: April 13, 2026

Consultative, Proactive Physical Therapy in Early Multiple Sclerosis.

Consultative, Proactive Physical Therapy in Early Multiple Sclerosis.

Journal: International journal of MS care

Published: December 04, 2024

Cerebrovascular hemodynamics association with brain structure and function in Multiple Sclerosis.

Cerebrovascular hemodynamics association with brain structure and function in Multiple Sclerosis.

Journal: Multiple sclerosis and related disorders

Published: May 16, 2024

Editorial: Cytokines and CNS diseases.

Editorial: Cytokines and CNS diseases.

Journal: Frontiers in cellular neuroscience

Published: November 08, 2023

Case report: Use of granulocyte-colony stimulating factor as an immunomodulatory therapy in a patient with neuromyelitis optica spectrum disorder and comorbid immunodeficiency.

Case report: Use of granulocyte-colony stimulating factor as an immunomodulatory therapy in a patient with neuromyelitis optica spectrum disorder and comorbid immunodeficiency.

Journal: Frontiers in neurology

Published: June 19, 2023

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.

Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.

Journal: CNS drugs

Published: February 13, 2023

Differential Diagnosis of Tumor-like Brain Lesions.

Differential Diagnosis of Tumor-like Brain Lesions.

Journal: Neurology. Clinical practice

Published: February 03, 2023

Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.

Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.

Journal: Brain : a journal of neurology

Published: January 27, 2023

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis.

Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis.

Journal: Neurology and therapy

Published: December 20, 2022

Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity.

Neurologic Manifestations of Long COVID Differ Based on Acute COVID-19 Severity.

Journal: Annals of neurology

Published: November 17, 2022

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.

Journal: CNS drugs

Published: August 21, 2022

Can Immune Tolerance Be Re-established in Neuromyelitis Optica?

Can Immune Tolerance Be Re-established in Neuromyelitis Optica?

Journal: Frontiers in neurology

Published: September 25, 2021

Showing 1-12 of 35

Last Updated: 09/26/2026